BioNTech to pay $1.2 billion over vaccine royalties
BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is trading at $114.25, up 0.42 percent on the Nasdaq.
BioNTech Settles Royalty Dispute with University of Pennsylvania
BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn,
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...
BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...
The ADR's fall snapped a three-day winning streak.
In a report released on December 6, Daina Graybosch from Leerink Partners maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Tidal Investments LLC lessened its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 39.5% in the third quarter, ...
Bengaluru: German biotechnology company BioNTech has reached two separate settlement agreements with the U.S. National ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioNTech SE (BNTX – Research Report), Vertex Pharmaceuticals ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback